Jim Hoffman: Thrombomodulin as a Key Regulator of Coagulation and Inflammation
Jim Hoffman, Former Technical Advisor at Cygnus Technologies, LLC, shared a post on LinkedIn about an article by Yasuyo Shimomura et al. published in Journal of Intensive Care, adding:
“Thrombomodulin (TM) is a protein that plays a crucial role in regulating coagulation and inflammation.
It is primarily expressed on the cell surface of endothelial cells, but its soluble form exists in the circulation as well.
TM, when optimally dosed, has been demonstrated to exert a protective effect against greater endothelial dysfunction and vascular damage during experimental sepsis and coagulopathy.
Recombinant human-soluble TM (rTM) administration has been used in humans, primarily in Japan, for the treatment of sepsis and hematological malignancy-associated disseminated intravascular coagulation DIC, reducing the severity of vascular injury since 2008.
In the context of dysregulated NETosis, which is also prevalent DIC progression, resulting in greater vascular injury, TM is known to inhibit platelet and LPS-facilitated NETosis induction in vitro.
Based on the work of Toh et al., and the enlightening research of many other NETosis investigators; NETosis dysregulation should be directly targeted by extracorporeal depletion therapy to reduce DIC severity and reduce the risk of life-threatening immunothrombotic ischemic events.
NETosis induction and impaired chromatin/NET clearance from the blood positively correlate with an increased risk of life-threatening disseminated intravascular coagulation and ischemic circulatory failure events.”
Title: Recombinant human thrombomodulin inhibits neutrophil extracellular trap formation in vitro
Authors: Yasuyo Shimomura, Mika Suga, Naohide Kuriyama, Tomoyuki Nakamura, Toshikazu Sakai, Yu Kato, Yoshitaka Hara, Chizuru Yamashita, Hiroshi Nagasaki, Masao Kaneki, Osamu Nishida

Stay updated on all scientific advances Hemostasis Today.
-
Nov 11, 2026, 15:42Tareq Abadl: The Clinical Impact of Kell Alloimmunization
-
Nov 11, 2026, 15:30Alejandro González Veliz: Does PCI Change The Long-Term Outcome In Stable Coronary Artery Disease?
-
Nov 11, 2026, 15:25Preparing for the SoHO Regulation – EBA Board Convenes in Vienna – European Blood Alliance
-
Nov 11, 2026, 15:20Vaidehi Prasanth: IV Iron in Heart Failure – Exploring Hospitalisation Benefits vs. Infection Risk in Open Heart
-
Nov 11, 2026, 15:18Stefan Prendić: Can Algorithms Support Antibody Identification in Immunohematology?
-
Nov 11, 2026, 15:12Perioperative Challenges in Hemophilia Patients on Rebalancing Therapies
-
Nov 11, 2026, 15:03Maria Elisa Mancuso: World-Renowned Faculty and 33 Global Participants Unite at Hemophilia Academy 2026
-
Nov 11, 2026, 15:01Hassan Raza: The JAK2 V617F Revolution
-
Nov 11, 2026, 14:57Edward Lee Carter: Factor Xla Inhibition Enters Clinical Practice – FDA Approval of Asundexian